Israel’s SciVac eyes global expansion of 3G hepatitis B vaccine

An employee checks a hepatitis B vaccine, at SciVac's laboratory in RehovotBy Steven Scheer REHOVOT, Israel (Reuters) – Israeli drug company SciVac is seeking U.S. approval for a widely used hepatitis B vaccine as part of a push for increased global sales of a product which it says could stem global growth in the disease. Some 1.2 million people die each year from HBV, 100 times more than HIV, while as many as 400 million people are carriers. SciVac – 45 percent owned by Opko Health, which is controlled by Teva Pharmaceutical Industries Chairman Phillip Frost – has applied to the U.S. …



Sexual Health News Headlines – Yahoo! News